| abstract |
REFERS TO COMPOUNDS DERIVED FROM PIPERIDINE OR PYRROLIDINE UREAS OF FORMULA (I) WHERE X IS C, O, S OR SO2; R1a, R1b, R1c, R1d, R2a, R2b, R2c AND R2d ARE EACH H, HALOGEN, ALKYL (C1-C5), ALCOXY (C1-C5), HALOGENOALKYL (C1-C5), CN, AMONG OTHERS; R3a AND R3b ARE EACH H, F, ALKYL (C1-C5), ALCOXY (C1-C5), OH, CN, AMONG OTHERS; R4 IS ALKYL (C1-C5), CYCLOALKYL (C3-C6), ARYL (C5-C10), AMONG OTHERS, OPTIONALLY SUBSTITUTED WITH HALOGEN, CN, PHENYL, BENZYL, AMONG OTHER SUBSTITUTES; n IS 0 O 1; o, p, q AND r ARE EACH FROM 0 TO 2; i AND j ARE EACH FROM 0 TO 4. THE PREFERRED COMPOUNDS ARE: 1 '- (3,4-DIHYDROQUINOLIN-1 (2H) -ILCARBONYL) SPYRO [INDENO-1,4-PIPERIDINE], 1' - (3,4 -DIHYDROQUINOLIN-1 (2H) -ILCARBONYL) SPIROINDENE-4,4'-PIPERIDINE, 4 - [(3-PYRIDIN-3-ILPYRROLIDIN-1-IL) CARBONYL] -3,4-DIHYDRO-2H-1, 4-BENZOXAZINE, AMONG OTHERS. IT ALSO REFERS TO A PREPARATION PROCEDURE AND A PHARMACEUTICAL COMPOSITION. SAID COMPOUNDS ARE MODULATORS OF 11B-HYDROXIESTEROID DEHYDROGENASE TYPE 1 (11BHSD1) BEING USEFUL IN THE TREATMENT OF OBESITY, DIABETES, METABOLIC SYNDROME, GLAUCOMA |